Immutep (IMMP) News Today $1.92 -0.05 (-2.54%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.98 +0.06 (+3.07%) As of 02/21/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?February 11, 2025 | insidermonkey.comImmutep (NASDAQ:IMMP) Stock Passes Below 50-Day Moving Average - Time to Sell?Immutep (NASDAQ:IMMP) Shares Pass Below 50-Day Moving Average - What's Next?February 5, 2025 | marketbeat.comImmutep reports quarterly activities and financialsFebruary 4, 2025 | msn.comImmutep Advances to Phase III with Key Approvals and Promising Trial ResultsFebruary 3, 2025 | tipranks.comImmutep Limited: Immutep Quarterly Activities Report Q2 FY25January 31, 2025 | finanznachrichten.deImmutep promotes Christian Mueller to CDO, CMO Florian Vogl to departJanuary 31, 2025 | markets.businessinsider.comImmutep reports Q2 cash receipts from customers A$8,000January 31, 2025 | markets.businessinsider.comImmutep Limited Announces Transition to Phase III with Regulatory Approval for TACTI-004 Trial in Non-Small Cell Lung CancerJanuary 31, 2025 | quiverquant.comImmutep Quarterly Activities Report Q2 FY25January 31, 2025 | globenewswire.comIs Immutep Limited (IMMP) One of the Best ASX Stocks to Buy According to Hedge Funds?January 31, 2025 | insidermonkey.comImmutep Limited: Continuing To Make The Case For EftilagimodJanuary 28, 2025 | seekingalpha.comPatient Enrolment Completed for EFTISARC-NEO Phase II TrialJanuary 22, 2025 | markets.businessinsider.comImmutep (NASDAQ:IMMP) Stock Passes Below Fifty Day Moving Average - What's Next?Immutep (NASDAQ:IMMP) Stock Price Crosses Below Fifty Day Moving Average - Here's WhyJanuary 22, 2025 | marketbeat.comImmutep Completes Patient Enrolment for Key Phase II Cancer TrialJanuary 21, 2025 | tipranks.comImmutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 51% of the companyJanuary 16, 2025 | au.finance.yahoo.comImmutep (NASDAQ:IMMP) Share Price Crosses Below Fifty Day Moving Average - Should You Sell?Immutep (NASDAQ:IMMP) Shares Cross Below Fifty Day Moving Average - Here's WhyJanuary 14, 2025 | marketbeat.comImmutep (NASDAQ:IMMP) Stock Crosses Above 50-Day Moving Average - What's Next?Immutep (NASDAQ:IMMP) Stock Price Crosses Above 50 Day Moving Average - Here's WhyDecember 26, 2024 | marketbeat.comImmutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761December 17, 2024 | globenewswire.comImmutep, Monash University announce publication on human LAG-3December 17, 2024 | markets.businessinsider.comImmutep (NASDAQ:IMMP) Shares Down 4.6% - Here's What HappenedImmutep (NASDAQ:IMMP) Stock Price Down 4.6% - Time to Sell?December 17, 2024 | marketbeat.comImmutep Reveals Promising Data for IMP761 TrialDecember 16, 2024 | tipranks.comImmutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class IIDecember 16, 2024 | markets.businessinsider.comImmutep’s Eftilagimod Alpha Shows Promising Results in Head and Neck Cancer Study, Justifying Buy RatingDecember 14, 2024 | markets.businessinsider.comImmutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024December 12, 2024 | globenewswire.comImmutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung CancerDecember 11, 2024 | finance.yahoo.comImmutep Initiates Phase III Trial for Lung CancerDecember 9, 2024 | tipranks.comImmutep: Potential Of Efti As New Standard Of Care For NSCLC PatientsNovember 15, 2024 | seekingalpha.comImmutep (NASDAQ:IMMP) Given New $7.00 Price Target at Robert W. BairdRobert W. Baird raised their target price on shares of Immutep from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday.November 15, 2024 | marketbeat.comImmutep ADRs Climb on Positive Efti Trial ResultsNovember 14, 2024 | marketwatch.comImmutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung CancerNovember 14, 2024 | markets.businessinsider.comImmutep Announces Positive Data From INSIGHT-003 Trial In Non-Small Cell Lung Cancer, Stock UpNovember 14, 2024 | markets.businessinsider.comImmutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer TrialNovember 14, 2024 | benzinga.comImmutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung CancerNovember 14, 2024 | globenewswire.comImmutep (NASDAQ:IMMP) Stock Price Passes Below Fifty Day Moving Average - Here's What HappenedImmutep (NASDAQ:IMMP) Shares Cross Below Fifty Day Moving Average - Here's WhyNovember 8, 2024 | marketbeat.comImmutep Quarterly Activities Report Q1 FY25October 29, 2024 | globenewswire.comImmutep (NASDAQ:IMMP) Stock Price Crosses Below 50-Day Moving Average - Time to Sell?Immutep (NASDAQ:IMMP) Shares Cross Below Fifty Day Moving Average - Should You Sell?October 23, 2024 | marketbeat.comImmutep (NASDAQ:IMMP) Stock Price Crosses Below 50 Day Moving Average - Should You Sell?Immutep (NASDAQ:IMMP) Share Price Crosses Below Fifty Day Moving Average - Should You Sell?October 11, 2024 | marketbeat.comAnnovis Bio (NYSE:ANVS) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.comImmutep to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 10, 2024 | globenewswire.comImmutep: Navigating The Bumps In The RoadOctober 7, 2024 | seekingalpha.comImmutep (NASDAQ:IMMP) Share Price Passes Above 50-Day Moving Average of $2.25Immutep (NASDAQ:IMMP) Shares Pass Above 50 Day Moving Average of $2.25September 26, 2024 | marketbeat.comImmutep Receives A$3.6 million R&D Tax Incentive from French GovernmentSeptember 24, 2024 | finance.yahoo.comNew Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue SarcomaSeptember 18, 2024 | markets.businessinsider.comDow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In SeptemberSeptember 16, 2024 | msn.comBuy Rating for Immutep: Promising Developments in Oncology and Competitive EdgeSeptember 16, 2024 | markets.businessinsider.comImmutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck CancerSeptember 16, 2024 | markets.businessinsider.comImmutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck CancerSeptember 16, 2024 | globenewswire.comFY2025 EPS Estimates for Immutep Limited (NASDAQ:IMMP) Increased by AnalystImmutep Limited (NASDAQ:IMMP - Free Report) - Research analysts at Capital One Financial lifted their FY2025 earnings per share estimates for shares of Immutep in a report issued on Tuesday, September 3rd. Capital One Financial analyst N. Quibria now forecasts that the biotechnology company willSeptember 6, 2024 | marketbeat.comFY2029 EPS Estimates for Immutep Limited Raised by Capital One Financial (NASDAQ:IMMP)Immutep Limited (NASDAQ:IMMP - Free Report) - Analysts at Capital One Financial lifted their FY2029 earnings per share (EPS) estimates for Immutep in a research report issued to clients and investors on Tuesday, September 3rd. Capital One Financial analyst N. Quibria now forecasts that the biotecSeptember 5, 2024 | marketbeat.comImmutep Limited (NASDAQ:IMMP) Short Interest UpdateImmutep Limited (NASDAQ:IMMP - Get Free Report) was the recipient of a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 4,730,000 shares, a drop of 10.1% from the July 15th total of 5,260,000 shares. Based on an average trading volume of 372,100 shares, the days-to-cover ratio is presently 12.7 days.August 18, 2024 | marketbeat.com Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address IMMP Media Mentions By Week IMMP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMMP News Sentiment▼0.000.60▲Average Medical News Sentiment IMMP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMMP Articles This Week▼01▲IMMP Articles Average Week Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 89bio News Gyre Therapeutics News Aurinia Pharmaceuticals News Intellia Therapeutics News Maravai LifeSciences News Enliven Therapeutics News Phibro Animal Health News Zymeworks News AbCellera Biologics News Replimune Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMMP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immutep With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
